Browse articles from EyeWorld.org related to IOLs. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ 36-month results from first-in-human study with shape-changing IOL
➤ New data for recently approved EDOF IOL
➤ Company completes first-in-human robotic cataract surgery
➤ Phase 2 study approved for secondary IOL intended for low-vision patients
➤ Investigational device measures real-time intraoperative aqueous outflow
➤ FDA expands dosing on label for faricimab
➤ Company news
➤ ASCRS news and events
➤ Keep up with ASCRS Annual Meeting coverage with EyeWorld Onsite
➤ Positive topline results from Phase 3 trial for TED drug with new delivery method
➤ FDA expands dosing interval for wet AMD, DME treatment
➤ IDE granted to noninvasive bioelectric stimulation therapy for dry AMD
➤ First patients dosed in Phase 3 corneal cell therapy
➤ TED investigational treatment fails to meet primary endpoint
➤ OTC eye drop recall after FDA enforcement report cites sterility concerns
➤ ASCRS news and events
With expanding lens options in cataract surgery and an increase in combined glaucoma and cataract procedures, two ophthalmologists went into detail on when the Light Adjustable Lens (LAL, RxSight) can be a good option for glaucoma patients and considerations when choosing it.
EyeWorld spoke with two experts on the topic of when the Ks don’t align—when misalignment is clinically significant, what can be done about it, and how it impacts lens choices.
➤ FDA approves new EDOF with limited dysphotopsias
➤ Phase 1/2 12-month data for IOL-based drug delivery system
➤ Topline results from Phase 2a wet AMD study
➤ FDA grants Breakthrough Device Designation to brain implant technology
➤ FDA allows Phase 1/2 trial to begin for investigational cell therapy for familial drusen
➤ ASCRS news and events
➤ First patient treated with novel crosslinking approach for refractive error
➤ Multisociety working group established to set guidelines for modern IOL classification
➤ FDA reduces clinical trial requirement for new drugs to one pivotal trial
➤ ASCRS news and events
➤ New drop for temporary presbyopia relief approved
➤ First-in-human results for accommodating IOL
➤ Enrollment complete in Phase 2/3 trial for Stargardt therapy
➤ Type C meeting completed with FDA to advance urcosimod for neuropathic corneal pain
➤ Company news
➤ ASCRS news and events
➤ FDA review extended for dry eye disease treatment
➤ Key data gathered for expected NDA submission
➤ Phase 2b results for GA treatment
➤ Phase 3 studies discontinued for thyroid eye disease
➤ ASCRS news and events
The University of Washington ophthalmology residents reviewed “Long term efficacy and safety of iris-claw phakic intraocular lens in the management of post keratoplasty astigmatism” from the December issue of the Journal of Cataract & Refractive Surgery.
While not a common approach or its primary indication, the ICL (STAAR Surgical) can be used as a supplementary/piggyback IOL in some patients. Three physicians discussed how this off-label approach to using the ICL is opening doors to treat certain patients.
